The Latest Breaking News from VTRS

Viatris has lagged the broader Nasdaq Composite over the past year, and Wall Street sentiment toward the stock remains guarded.

In the latest investment moves, Greenlight Capital (NASDAQ:GLRE), led by David Einhorn, has disclosed its Q2 2025 13F filing trades.

Viatris has underperformed the broader market over the past year, and analysts remain skeptical of the stock’s future potential.

Viatris is scheduled to report its first-quarter results next month, and analysts expect a double-digit earnings drop.

Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.

As Viatris has trailed the broader market over the past year, analysts are skeptical about its future outlook.

Healthcare’s resilience makes it a go-to sector during market volatility. With steady demand, innovation, and aging demographics driving growth, investors could consider investing in fundamentally sound stocks like Viatris (VTRS), Bausch + Lomb Corp. (BLCO), and ACADIA Pharmaceuticals (ACAD). With strong industry tailwinds and discounted valuations, these stocks could offer…

Despite Viatris’ recent outperformance relative to its broader sector, Wall Street analysts remain cautious about the stock’s prospects.

Due to Viatris’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain cautious about the stock’s prospects.